Switching multiple sclerosis patients with breakthrough disease to second-line therapy. - Wikidata - awgldk - TriplyDB

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

http://www.wikidata.org/entity/Q33815455

about

Optimizing treatment success in multiple sclerosis What went wrong? The flawed concept of cerebrospinal venous insufficiency.Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.Patient perspectives on switching disease-modifying therapies in the NARCOMS registry.Extended interval dosing of natalizumab: a two-center, 7-year experience Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis.From injection therapies to natalizumab: views on the treatment of multiple sclerosis.Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Long-term evolution of multiple sclerosis disability in the treatment era.Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany.Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings The transition from first-line to second-line therapy in multiple sclerosis.Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.Switching therapies in multiple sclerosis.Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.Are randomized, blind clinical trials enough to guide individualized decisions for patients with neurologic diseases?Incorporating real-world clinical practice in multiple sclerosis economic evaluations.Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

P2860

Q26771968-11BEFB13-F6D7-4619-A2A9-C23BFB9F3ACF Q30454634-5E673248-EE8B-4BA1-8CB0-664764B7EADE Q33642908-35648DA4-4AD2-4682-A278-4AD7AD2F3B10 Q33890415-BBD0010E-E186-4151-8607-4EAC84097D94 Q34389306-BDCADB28-26D4-4F66-8488-B1C21EEA676B Q35109078-F3B5FA7A-1E67-4CC3-A7FB-8D287BF27DC9 Q35342948-C40D1C9A-F246-4206-87FE-FB6C559D0C45 Q35825914-55CD0B59-189C-4377-9B02-CEA53EDD9DAD Q36648907-F2065120-0862-4D93-85A9-8DE45A0026F8 Q36951371-66FC182B-1A75-4C05-80C7-8A50D0BAC25E Q36975701-D5D50F38-03FD-4E72-860D-53BEA756783A Q37409279-44C88E68-CC72-442A-9BBB-AA1CB498B4BB Q37412487-B4EB02C5-C249-4A36-9399-E0C05CCEBCC2 Q37422818-30CF10C6-B2A7-48A4-B186-66E99A4B6C52 Q37626336-A9BD0CB3-C98E-4A5B-A36C-B89CC1737203 Q37922644-CEF83717-F072-457D-BAF9-84DB1094B0FD Q38163046-9BC043ED-012B-4FF9-8CAC-2A97E1B3F0EB Q38268313-DF3F904A-0809-4BC7-8CBC-246F7DE33896 Q38946338-E007E700-66F0-49B2-A0C1-69251D3015E3 Q40498719-D1861467-4A1E-4B8A-924B-6EF368B5019D Q41014662-1AF4429C-E8D4-4F07-BF45-7DA1DE85EF03 Q42223350-837E26DC-A06D-4967-9D9E-4990DE1ADD18 Q45977173-26B7588A-5BF9-452C-8C27-DA41B58F4A30 Q46835552-A31DEE0B-370C-4CD9-B594-20024C66C4AD Q46870849-7FE21F46-D833-43D2-8AB6-26085578D5BC Q47865523-A1F78484-3A82-42F7-8930-137D71AEF079 Q48956772-A33063AD-402B-49F2-9E5A-FFDE465E5CCF Q50223030-88FEFEAE-54DB-4091-9209-AEBBD2334522 Q50976326-B4008BF4-9254-4B1D-B239-FDDBA0B5237B Q57601861-14B49E58-7096-4B19-92BB-69C0FC3E08E6

P2860

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

http://www.wikidata.org/entity/Q33815455

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

@ast

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

@en

type

label

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

@ast

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

@en

prefLabel

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

@ast

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

@en

P1433

Q33815455-6C2B98AA-A700-4E2D-81C5-8EEDA4FA4277

P1476

Q33815455-C46C74E5-8E4C-415E-BB60-9B3990A298BC

P2093

Q33815455-06918AD5-10BF-4960-B160-C2685526E781

Q33815455-176BBE93-51B8-40ED-91C7-5EFE020B9FBF

Q33815455-67794BDE-D05B-489D-8D45-5D4C51CA86A3

Q33815455-885FEB2A-F4B5-42DC-9029-94EC60741FAA

Q33815455-9261EC6E-35DB-4C35-A129-828943454E3E

Q33815455-B545FA44-4227-4A11-88C8-9F930BD2B09F

Q33815455-C4E14361-8092-4727-97E7-048629AECBF9

Q33815455-D80C1683-C5F9-410C-B294-1D5B37FCD531

Q33815455-DC60D2BF-8058-4042-A312-F500B3C89969

Q33815455-E26AEF0B-BD8A-4BF6-B074-AC338A2D3E9C

P2860

Q33815455-03A393BE-E742-4FD4-9E87-1DDCE71B8BDD

Q33815455-1028A12E-F8A3-4479-B4F0-A1C580BBC98A

Q33815455-10A50E48-C0D5-4642-942A-12A17BCEE6F4

Q33815455-575C53FF-DACB-4CD6-BDB5-72AEB0AC6664

Q33815455-71E74240-97FC-4A70-B101-F969CB38B60B

Q33815455-7688203C-3E0A-4C9E-B2D2-40E89C8DFC86

Q33815455-832B6785-95E1-4D8B-9C22-FC7C58156509

Q33815455-8606A52E-B6B9-4395-A300-0F6081456D73

Q33815455-8B4629CE-AC2C-412B-AA0E-FC4E281A087B

Q33815455-B5371195-726B-4FA6-BC46-48D78811F574

P304

Q33815455-92C29493-4BCC-4D48-A269-C94BEC00C8C9

P31

Q33815455-0FB005B3-576D-4B52-84DC-1E9DBD695AC6

P356

Q33815455-F34A7F3F-8DB8-4700-94C9-415E93F06D53

P407

Q33815455-1BBB5171-9224-49F6-A69D-6EA81FDDDB78

P433

Q33815455-F47D129F-DDA2-4DEE-83CC-9007162D526F

P478

Q33815455-4C9773DB-212F-4E0C-AD22-AFC9D6CCA375

P50

Q33815455-860BC66F-F82F-4044-9D7E-C8F60AF63518

Q33815455-BE882E43-05FD-4CC7-8AE7-1C948D3CE40C

Q33815455-F3C8ED0E-7A0B-4906-A98A-84FDF8450CE5

P577

Q33815455-114B1FCD-4F34-492F-99FD-B166D9DAE13A

P5875

Q33815455-EEB5DBF7-B055-405B-B927-89FDFA4EE63E

P698

Q33815455-FAB0A550-0BDF-4BD3-8658-3117D7E37871

P921

Q33815455-F09DCFE6-22A1-4683-AF93-AB638EC97E4B

P932

Q33815455-E774BF46-629F-472A-8A6A-0210751820FD

P356

JOURNAL.PONE.0016664

P1433

P1476

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

@en

P2093

Ari J Green

http://www.w3.org/2001/XMLSchema#string

Bruce A Cree

http://www.w3.org/2001/XMLSchema#string

Daniel Pelletier

http://www.w3.org/2001/XMLSchema#string

Darin T Okuda

http://www.w3.org/2001/XMLSchema#string

Dorothee Chabas

http://www.w3.org/2001/XMLSchema#string

Douglas S Goodin

http://www.w3.org/2001/XMLSchema#string

Elizabeth Crabtree-Hartman

http://www.w3.org/2001/XMLSchema#string

Ellen M Mowry

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

Tamara Castillo-Trivino

http://www.w3.org/2001/XMLSchema#string

P2860

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

Clinical characteristics of responders to interferon therapy for relapsing MS.

P304

e16664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0016664

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuelle Waubant

Eric Vittinghoff

Alberto Gajofatto

P577

2011-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49820934

http://www.w3.org/2001/XMLSchema#string

P698

21304907

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3033401

http://www.w3.org/2001/XMLSchema#string